New research shows obesity-associated immune checkpoint inhibitor efficacy depends on the diet–gut microbiome axis rather than metabolic dysfunction. Human-to-mouse fecal microbiota transplants from high-BMI donors enhanced ICI efficacy, while a review outlines obesity-related inflammation's role in lung cancer immunotherapy outcomes and biomarkers.
A Feb. 20, 2026 study in the Journal of Experimental Medicine identified CD8 T cell-derived TNF and TNFR2 signaling as drivers of ICI-related myocarditis in mice. Blocking TNFR2 prevented the inflammatory cycle in the heart.
A Phase 3 trial shows administering immunochemotherapy before 3:00 PM improves survival outcomes in advanced NSCLC. Early treatment resulted in 11.3 months progression-free survival versus 5.7 months for late treatment, and 28.0 months overall survival versus 16.8 months. The findings suggest treatment timing is a modifiable factor that can enhance efficacy without additional cost.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07804225 |
Cancer Nutrition Study - A Study of Dietary Interventions in Cancer Patients Treated With Immune Checkpoint Inhibitors |
NOT_YET_RECRUITING | NA |
